A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Trial Profile

A Phase Ib Study of the Safety and Pharmacology of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) Administered Alone or in Combination With Azacitidine in Patients With Myelodysplastic Syndromes

Recruiting
Phase of Trial: Phase I

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs Atezolizumab (Primary) ; Azacitidine
  • Indications Myelodysplastic syndromes
  • Focus Adverse reactions
  • Sponsors Roche
  • Most Recent Events

    • 25 Jun 2017 Results (n=16) presented at the 22nd Congress of the European Haematology Association
    • 16 Feb 2017 Time frame of primary end point has been changed from Up to approximately 18 months to Baseline up to approximately 3.5 years
    • 01 Nov 2016 Planned number of patients changed from 46 to 40.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top